Genetic Status Affects Disease-Specific Mortality But Not the Incidence of Local Recurrence in Patients with Uveal Melanoma.

Chromosome 3 Chromosome 8q Disease-specific survival Local recurrence Uveal melanoma

Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
08 2023
Historique:
received: 24 10 2022
revised: 08 03 2023
accepted: 10 03 2023
medline: 24 7 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

Increased disease-specific mortality has been observed among patients with local recurrence (LR) from uveal melanoma (UM), but the underlying mechanism is unknown. The purpose of this study was to determine if copy number alterations of chromosomes 3 and/or 8q, at the time of diagnosis, increase the incidence of LR and if disease-specific mortality among patients with LR depends on the chromosome status of the primary tumor. Retrospective cohort study. The study included 239 consecutive patients with primary UM (choroidal or ciliary body) treated with Ruthenium-106 (Ru-106) brachytherapy from January 2009 to December 2019 at a single national referral center. Cox regression modeling and Kaplan-Meier analyses were used to assess the effect of the status of chromosomes 3 and 8q on the incidence of LR and disease-specific mortality after the event of LR. Multistate models were used to illustrate the probabilities over time of patients being alive and disease-free, alive with LR, dead from UM metastases, or dead from other causes split on the status of chromosomes 3 and 8q. Incidence of LR and disease-specific mortality. Local recurrence was observed in 42 patients (16%). Overall incidence of LR was not affected by aberrations of chromosomes 3 and/or 8q (P = 0.87). Although LR occurred earlier in patients with aberrations of chromosomes 3 and/or 8q compared with patients with a normal copy number of chromosomes 3 and 8q, the median time from primary diagnosis to LR was 1.6 years (interquartile range [IQR], 1.0-2.0) and 3.2 years (IQR, 2.1-5.0), respectively. Cox regression found LR to be an independent risk factor for disease-specific mortality (hazard ratio [HR], 2.7; 95% confidence interval [CI], 1.5-5.0) among all patients, but multistate models demonstrated a low risk of disease-specific death among patients with normal chromosomes 3 and 8q status, even after an LR. Copy number alterations of chromosome 3 and/or 8q in the primary UM did not increase the overall incidence of LR. However, the development of an LR enhanced the risk of disease-specific mortality among patients with copy number alterations of chromosomes 3 and/or 8q. Even after an LR, disease-specific mortality remained low among patients with normal copy numbers of chromosomes 3 and 8q. The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Identifiants

pubmed: 36934828
pii: S0161-6420(23)00164-1
doi: 10.1016/j.ophtha.2023.03.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

822-829

Informations de copyright

Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Mette Bagger (M)

Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: mette.marie.bagger@regionh.dk.

Charlotte Espensen (C)

Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Oncology (Section of Radiotherapy), Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Kristina Rasmussen (K)

Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Mehmet Dogrusöz (M)

Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands.

Martine J Jager (MJ)

Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands.

Ane Appelt (A)

Leeds Institute of Medical Research at St James's, University of Leeds, and Leeds Cancer Centre, St. James's University Hospital, Leeds, United Kingdom.

Jens F Kiilgaard (JF)

Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH